SLN Live signals | Maximize Profits with Getagraph.com

BUY 94647 min ago

@ $21.84

Issued: 14 Feb 2024 @ 15:27

Return: 3.66%

Previous signal: Feb 9 - 13:56

Previous signal: Sell

Return: -3.36 %

Live Chart Being Loaded With Signals

Commentary (19 Apr 2024 @ 16:00):

Stats
Today's Volume	305 611
Average Volume	229 512
Market Cap	1.05B
EPS	$0 ( 2024-03-13 )
Next earnings date	( $-0.230 ) 2024-05-21
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-15.61
ATR14	$0.0630 (0.28%)

Volume Correlation

Long: -0.01 (neutral)

Short: 0.45 (neutral)

Signal:(51.277) Neutral

Silence Therapeutics plc Correlation

10 Most Positive Correlations
ACER	0.891
MMAC	0.861
BOCH	0.831
EEIQ	0.824
HOUR	0.82
UPC	0.819
JJSF	0.819
REYN	0.818
KNSA	0.816
DOGZ	0.815

10 Most Negative Correlations
RMRM	-0.876
SIBN	-0.859
SNPO	-0.847
APOP	-0.836
INZY	-0.828
RPHM	-0.821
HHGC	-0.815
HJLI	-0.812
GAINL	-0.808
VLCN	-0.804

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Silence Therapeutics plc Correlation - Currency/Commodity

0.75
( moderate )

0.49
( neutral )

0.00
( neutral )

0.83
( strong )

-0.25
( neutral )

-0.87
( strong negative )

Silence Therapeutics plc Financials

Annual	2023
Revenue:	$25.38M
Gross Profit:	$15.06M (59.34 %)
EPS:	$-1.170

Q4	2023
Revenue:	$2.10M
Gross Profit:	$753 000 (35.87 %)
EPS:	$0

Q3	2023
Revenue:	$2.80M
Gross Profit:	$1.19M (42.57 %)
EPS:	$-0.220

Q2	2023
Revenue:	$9.10M
Gross Profit:	$6.27M (68.90 %)
EPS:	$-0.290

Financial Reports:

No articles found.

Silence Therapeutics plc

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver. It designs short interfering RNA molecules to harness the body's natural mechanism of RNA interference, and degrading messenger RNA molecules that encode specific targeted disease-associated proteins in a cell. The company is developing various product candidates, including SLN360, which is Phase I clinical trials for the treatment of cardiovascular disease with high lipoprotein; SLN124 that is in Phase I clinical trials for the treatment of non-transfusion dependent thalassemia, and Phase I clinical trials for the treatment of myelodysplastic syndrome; and SLN124 for the treatment of polycythemia vera. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize small interfering RNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company also has a collaboration with Hansoh Pharmaceutical Group Company Limited to develop siRNAs for three undisclosed targets leveraging Silence's mRNAi GOLD platform. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc is headquartered in London, the United Kingdom.